Tempol augments angiotensin II-induced AT2 receptor-mediated relaxation in diabetic rat thoracic aorta

Journal of Hypertension

Volumn 22, Issue 11, 2004, Pages 2143-2152

  Arun, K H S ^a   Kaul, Chamanlal L ^a   Poduri, Ramarao ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

Angiotensin II; AT2 receptors; N G nitro L arginine methyl ester; Rat; Superoxide dismutase; Tempol

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; 2,3 BUTANEDIONE; 4 AMINOPYRIDINE; ANGIOTENSIN; ANGIOTENSIN 2 RECEPTOR; BUTANEDIONE MONOXIME; CHOLERA TOXIN; GLIPIZIDE; INDOMETACIN; INSULIN; LOSARTAN; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE INHIBITOR; PERTUSSIS TOXIN; PHENYLEPHRINE; POTASSIUM CHANNEL; POTASSIUM CHLORIDE; STREPTOZOCIN; SUPEROXIDE DISMUTASE; TEMPOL; TETRYLAMMONIUM; UNCLASSIFIED DRUG; VALSARTAN;

ANIMAL EXPERIMENT; ARTICLE; BINDING ASSAY; BLOOD PRESSURE MEASUREMENT; CONTROLLED STUDY; DISSOCIATION CONSTANT; DRUG EFFECT; DRUG POTENTIATION; DRUG RECEPTOR BINDING; ENZYME ACTIVITY; INSULIN BLOOD LEVEL; MALE; MUSCLE RELAXATION; NONHUMAN; PRIORITY JOURNAL; RAT; RAT STRAIN; SMOOTH MUSCLE FIBER MEMBRANE; STREPTOZOCIN DIABETES; THORACIC AORTA; VASCULAR RING;

EID: 7744222161     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200411000-00017     Document Type: Article

References (45)

1. Lavoie JL, Sigmund CD. Overview of the renin-angiotensin system - an endocrine and paracrine system. Endocrinology 2003; 144:2179-2183.
2. Jagadeesh G. Angiotensin II receptors - Antagonists, molecular biology and signal transduction. Indian J Exp Biol 1998; 36:1171-1194.
3. Carey RM, Wang ZQ, Siragy HM. Role of the angiotensin type 2 receptor in the regulation of blood pressure and renal function. Hypertension 2000; 35:155-163.
4. Suzuki J, Iwai M, Nakagami H, Wu L, Chen R, Sugaya T, et al. Role of angiotensin II-regulated apoptosis through distinct AT1 and AT2 receptors in neointimal formation. Circulation 2002; 106:847-853.
5. Touyz RM, Berry C. Recent advances in angiotensin II signaling. Braz J Med Biol Res 2002; 35:1001-1015.
6. Wolf G. 'The road not taken': role of angiotensin II type 2 receptor in pathophysiology. Nephrol Dial Transplant 2002; 17:195-198.
7. Unger T, Culman J, Gohike P. Angiotensin II receptor blockade and end organ protection: pharmacological rationale and evidence. J Hypertens 1998; 16:53-9.
8. 2 receptor in the brain in regulation of blood pressure and water intake. Am J Physiol Heart Circ Physiol 2003; 284:H116-121.
9. Matsukawa T, Ichikawa I. Biological functions of angiotensin and its receptors. Annu Rev Physiol 1997; 59:395-412.
10. 2 receptor signaling pathway in ng108-15 cells. J Biol Chem 2003; 278:3606-3614.
11. Gorelik G, Carbini LA, Scicli AG. Angiotensin 1-7 induces bradykinin-mediated relaxation in porcine coronary artery. J Pharmacol Exp Ther 1998; 286:403-410.
12. 2 receptors in modulating coronary microvascular function. Circ Res 2003; 92:322-329.
13. Cordonnier D, Zaoui P, Halimi S. Role of ACE inhibitors in patients with diabetes mellitus. Drugs 2001; 61:1883-1892.
14. 2 receptors in peripheral tissues of neonatal and adult rats. Regul Pept 1996; 65:159-164.
15. 4 receptors. J Hypertens 1998; 16:2027-2037.
16. Takeuchi K. Signal transduction systems of angiotensin II receptors. Nippon Rinsho 1999; 57:1070-1077.
17. 2 receptor-dependent vasodilation is mediated by activation of vascular kinin generation under flow conditions. Br J Pharmacol 2002; 136:484-491.
18. 2+ signaling. Am J Physiol Heart Circ Physiol 2003; 284:H779-789.
19. 2-subtype receptors prevents the effect of angiotensin II on the rat vascular structure. J Clin Invest 1996; 98: 418-425.
20. 2 receptor stimulation increases aortic cyclic GMP in SHRSP by bradykinin-dependent mechanism. Hypertension 1998; 321:349-355.
21. Shastri S, Robert McNeil J, Thomas WW, Ramarao P, Kaul CL, Gopalakrishnan V. Cysteinyl leukotrienes mediate enhanced vasoconstriction to angiotensin II but not endothelin I in SHR. Am J Physiol Heart Circ Physiol 2001; 281:H342-349.
22. Srikumar BN, Shailesh S, Ramarao P, Kaul CL. Selective attenuation of enhanced angiotensin II mediated responses in the streptozotocin diabetic rat thoracic aorta by tempol. In: Pierce GN, Nagano P, Dhalla NS (editors): Atherosclerosis, hypertension and diabetes. Boston: Kluwer Academic Publishers; 2003, pp. 327-337.
23. Meyer P, Flammer J, Luscher TF. Local action of the renin angiotensin system in the porcine ophthalmic circulation: effects of ACE-inhibitors and angiotensin receptor antagonists. Invest Ophthalmol Vis Sci 1995; 36:555-562.
24. Maillard MP, Lucia M, Véronique D, Catherine C, Jürg N, Hans RB, Michel B. Assessment of angiotensin II receptor blockade in humans using a standardized angiotensin II receptor-binding assay. Am J Hypertens 1999; 12:1201-1208.
25. Lowry O, Rosebrough N, Farr A, Randall R. Protein measurement with Folin phenol reagent. J Biol Chem 1951; 193:265-275.
26. Martin JP. Assay for superoxide dismutase based on autoxidation of hematoxylin. Methods Enzymol 1990; 186:220-227.
27. Thiyagarajan M, Kaul CL, Ramarao P. Enhancement of alpha-adrenoceptor- mediated responses in prostate of testosterone-treated rat. Eur J Pharmacol 2002; 453:335-344.
28. Shastri S, Gopalakrishnan V, Poduri R, Di Wang H. Tempol selectively attenuates angiotensin II evoked vasoconstrictor responses in spontaneously hypertensive rats. J Hypertens 2002; 20:1381-1391.
29. Costa RSA, Assreuy J. Nitric oxide inhibits irreversibly P815 cell proliferation: involvement of potassium channels. Cell Prolif 2002; 35:321-332.
30. + channel: a comparison with nifedipine. J Pharmacol Exp Trier 1991; 256:480-485.
31. + channels in isolated mouse pancreatic beta-cells by 2,3-butanedione monoxime. Br J Pharmacol 1994-112:143-149.
32. Arendshorst WJ, Brannstrom K, Ruan X. Actions of angiotensin II on the renal microvasculature. J Am Soc Nephrol 1999; 10:3149-161.
33. Arima S, Endo Y, Yaoita H, Omata K, Ogawa S, Tsunoda K, et al. Possible role of P-450 metabolite of arachidonic acid in vasodilator mechanism of angiotensin II type 2 receptor in the isolated microperfused rabbit afferent arteriole. J Clin Invest 1997; 100:2816-2823.
34. Champion HC, Bivalacqua TJ, Lambert DG, McNamara DB, Kadowitz PJ. The influence of candesartan and PD123319 on responses to angiotensin II in the hindquarters vascular bed of the rat. J Am Soc Nephrol 1999; 10:S95-97.
35. 2 receptors. J Cardiovasc Pharmacol 2002; 39:107-116.
36. Cardillo C, Kilcoyne CM, Cannon RO, Quyyumi AA, Panza JA. Xanthine oxidase inhibition with oxypurinol improves endothelial vasodilator function in hypercholesterolemic but not in hypertensive patients. Hypertension 1997; 30:57-63.
37. Wattanapitayakul SK, Weinstein DM, Holycross BJ, Bauer JA. Endothelial dysfunction and peroxynitrite formation are early events in angiotensin-induced cardiovascular disorders. FASEB J 2000; 14:271-278.
38. Yoshiaki T, Hiroaki M, Hiroya M, Hiroki Kurihara, Satoshi M, Shinji T, Mizuo M, et al. Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation. J Clin Invest 1999; 104:925-935.
39. 1A receptor in the development of 2K1C hypertension. Hypertension 2002; 40:735-741.
40. Hein L, Barsh GS, Pratt RE, Dzau VJ, Kobilka BK. Behavioral and cardiovascular effects of disrupting the angiotensin II type 2 receptor gene in mice. Nature 1995; 377:744-747.
41. Ichiki T, Labosky P, Shiota C, Okuyama S, Imagawa Y, Fogo A, et al. Effect on blood pressure and exploratory behavior of mice lacking angiotensin II type 2 receptor. Nature 1995; 377:748-750.
42. 2 knockout mice. Biochem Biophys Res Commun 1999; 258:194-198.
43. Horiuchi M, Akishita M, Dzau VJ. Recent progress in angiotensin II type 2 receptor research in the cardiovascular system. Hypertension 1999; 33:613-621.
44. Marta Ruiz O, Monica R, Vanesa E, Jesus E. Molecular mechanisms of angiotensin II-induced vascular injury. Curr Hypertens Rep 2003; 5:73-79.
45. Ghosh S, Sica D, Schoolwerth AC, Quigg RJ, Haas M, Fakhry I, Gehr TW. The role of the renin-angiotensin system in cholesterol and puromycin mediated renal injury. Am J Med Sci 2002; 324:296-304.